Sustained-Release of Flutamide from Radiation-Crosslinked Poly(4-acryloyl morpholine-acrylic acid) Hydrogels

Manal F. Abou Taleb; Samia El-Sigeny; Maged El-Kemary

Macromolecular Research, Vol.20, No.4, 407-414, April, 2012

DOI10.1007/s13233-012-0037-y Export Citation

Sustained-Release of Flutamide from Radiation-Crosslinked Poly(4-acryloyl morpholine-acrylic acid) Hydrogels

Manal F. Abou Taleb^{1, 2, †}, Samia El-Sigeny³, and Maged El-Kemary³

¹National Center for Radiation Research and Technology, P. O. Box No. 29, Nasr city, Cairo, Egypt
²Faculty of Science and Humanities Studies, Salman Bin Abdul Aziz University, Alkharj, Kingdom of Saudi Arabia
³Chemistry Department, Faculty of Science, Kafrelsheikh University, 33516, Kafr ElSheikh, Egypt

E-mail:

The present work reports the effect of radiation cross-linking on aqueous solution of 4-acryloyl morpholine (ACMO)/acrylic acid (AA) in the presence of flutamide (FLT), an anticancer drug. Use of a γ-irradiation process within 5 kGy provided an insoluble hydrogel. Ultraviolet-visible absorption, fluorescence spectroscopy, and Fourier transform infrared spectroscopy were employed to study the complex formation of FLT with ACMO and AA. The ability of the prepared ACMO/AA-based hydrogels to be used as drug carriers for anticancer-specific drug delivery system was estimated using FLT as a model drug. In vitro drug release studies in a pH 7 buffer solution show that 20%-30% of the FLT was continuously released from the FLT-incorporated ACMO/AA hydrogel within 1 day, followed by a gradual release upon 7 days under in vitro non-degradation hydrogel conditions. The recognition affinity of the ACMO/AA/FLT hydrogel is increased when synthesized in a high-concentration template solution.

Keywords:flutamide;γ-irradiation;fluorescence;drug;sustained-release;hydrogel.

[References]

Posti J, Katila K, Kostiainen T, Eur. J. Pharm. Biopharm., 49, 35 (2000)
Sweetman SC, Ed., Martindale, Complete Drug Reference, 34th ed., Pharmaceutical Press, London, 556 (2005)
Tzanavaras PD, Themelis DG, J. Pharm. Biomed.Anal., 43, 1820 (2007)
Asade RH, Prizont L, Muino JP, Tessler J, Cancer Chemother. Pharmacol., 27, 401 (1991)
Howell SB, Cancer J., 7, 219 (2001)
Bhattarai N, Gunn J, Zhang M, Adv. Drug Deliv. Rev., 62, 83 (2010)
Zhu Y, Ikoma T, Hanagata N, Kaskel S, Small., 6, 471 (2010)
Chen Y, Chen H, Zeng D, Tian Y, Chen F, Feng J, Shi J, ACS Nano., 4, 6001 (2010)
Giovanna P, Mariano L, Emanuela FC, Elio C, Giuseppe S, Gaetano GR, Physics and Chemistry., 65, 159 (2002)
Cruickshank R, Duguid JP, Marmion BP, Swain RHA, Churchill L, Medical Microbiology: The Practice of Medical Microbiology, Edinburgh, New York(2) (1975)
Baljit S, Nirmala C, Acta Biomater., 4, 1244 (2008)
Stalin T, Rajendiran N, J. Photochem. Photobiol. A:Chem., 182, 137 (2006)
Stalin T, Rajendiran N, Chem. Phys., 322, 311 (2006)
Anton SA, Manavalan R, Kannan K, Rajendiran N, J.Fluoresc., 20, 809 (2010)
Ishihara M, Obara K, Ishizuka T, Fujita M, Sato M, Masuoka K, Saito Y, Yura H, Matsui T, Hattori H, Kikuchi M, Kurita A, J. Biomed. Mater. Res., 64A, 248 (2003)
Tabata Y, Ikada Y, Biomaterials., 20, 2169 (1999)
Al-Taani BM, Tashtoush BM, AAPS PharmSciTech., 4, 110 (2003)
de Queiroz AAA, Abraham GA, Higa OZ, Acta Biomater., 2, 641 (2006)
Takka S, Rajbhandari S, Sakr A, Eur. J. Pharm. Biopharm., 52, 75 (2001)
Costa P, Int. J. Pharm., 220, 77 (2001)
Costa P, Lobo Sousa JM, Eur. J. Pharm. Sci., 13, 123 (2001)
Berger J, Reist M, Mayer JM, Felt O, Peppas NA, Gurny R, Eur. J. Pharm. Biopharm., 57, 19 (2004)
Ritger PL, Peppas NA, J. Control. Release., 5, 23 (1987)
Ritger PL, Peppas NA, J. Control. Release., 5, 37 (1987)
Tomic SL, Mic´ic´ MM, Filipovic´ JM, Suljovrujic EH, Radiat. Phys. Chem., 76, 801 (2007)
Abou Taleb MF, Abdel-Aal SE, El-Kelesh NA, Hegazy EA, Eur. Polym. J., 43, 468 (2007)

[1] Posti J, Katila K, Kostiainen T, Eur. J. Pharm. Biopharm., 49, 35 (2000)

[2] Sweetman SC, Ed., Martindale, Complete Drug Reference, 34th ed., Pharmaceutical Press, London, 556 (2005)

[3] Tzanavaras PD, Themelis DG, J. Pharm. Biomed.Anal., 43, 1820 (2007)

[4] Asade RH, Prizont L, Muino JP, Tessler J, Cancer Chemother. Pharmacol., 27, 401 (1991)

[5] Howell SB, Cancer J., 7, 219 (2001)

[6] Bhattarai N, Gunn J, Zhang M, Adv. Drug Deliv. Rev., 62, 83 (2010)

[7] Zhu Y, Ikoma T, Hanagata N, Kaskel S, Small., 6, 471 (2010)

[8] Chen Y, Chen H, Zeng D, Tian Y, Chen F, Feng J, Shi J, ACS Nano., 4, 6001 (2010)

[9] Giovanna P, Mariano L, Emanuela FC, Elio C, Giuseppe S, Gaetano GR, Physics and Chemistry., 65, 159 (2002)

[10] Cruickshank R, Duguid JP, Marmion BP, Swain RHA, Churchill L, Medical Microbiology: The Practice of Medical Microbiology, Edinburgh, New York(2) (1975)

[11] Baljit S, Nirmala C, Acta Biomater., 4, 1244 (2008)

[12] Stalin T, Rajendiran N, J. Photochem. Photobiol. A:Chem., 182, 137 (2006)

[13] Stalin T, Rajendiran N, Chem. Phys., 322, 311 (2006)

[14] Anton SA, Manavalan R, Kannan K, Rajendiran N, J.Fluoresc., 20, 809 (2010)

[15] Ishihara M, Obara K, Ishizuka T, Fujita M, Sato M, Masuoka K, Saito Y, Yura H, Matsui T, Hattori H, Kikuchi M, Kurita A, J. Biomed. Mater. Res., 64A, 248 (2003)

[16] Tabata Y, Ikada Y, Biomaterials., 20, 2169 (1999)

[17] Al-Taani BM, Tashtoush BM, AAPS PharmSciTech., 4, 110 (2003)

[18] de Queiroz AAA, Abraham GA, Higa OZ, Acta Biomater., 2, 641 (2006)

[19] Takka S, Rajbhandari S, Sakr A, Eur. J. Pharm. Biopharm., 52, 75 (2001)

[20] Costa P, Int. J. Pharm., 220, 77 (2001)

[21] Costa P, Lobo Sousa JM, Eur. J. Pharm. Sci., 13, 123 (2001)

[22] Berger J, Reist M, Mayer JM, Felt O, Peppas NA, Gurny R, Eur. J. Pharm. Biopharm., 57, 19 (2004)

[23] Ritger PL, Peppas NA, J. Control. Release., 5, 23 (1987)

[24] Ritger PL, Peppas NA, J. Control. Release., 5, 37 (1987)

[25] Tomic SL, Mic´ic´ MM, Filipovic´ JM, Suljovrujic EH, Radiat. Phys. Chem., 76, 801 (2007)

[26] Abou Taleb MF, Abdel-Aal SE, El-Kelesh NA, Hegazy EA, Eur. Polym. J., 43, 468 (2007)